Subscribe
e.g. organoids

Astellas Zolbetuximab Trial Results Cement CLDN18.2 as Pan-Cancer Biomarker

Astellas Pharma has announced positive results from a large Phase III trial (SPOTLIGHT) of zolbetuximab in CLDN18.2-positive and HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.
[Astellas Pharma (Genetic Engineering & Biotechnology News)]
Press Release
Published In
NewslettersEndothelial Cell News
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News

Therapeutic Blockade of ER Stress and Inflammation Prevents NASH and Progression to HCC

[Science Advances] Scientists used single-nucleus RNA sequencing to characterize a mouse model that mimicked human nonalcoholic steatohepatitis (NASH)–driven HCC, the MUP-uPA mouse fed a high-fat diet.
Hepatic Cell NewsNewsletters
Read more

Direct Mechanical Exposure Initiates Hepatocyte Proliferation

[JHEP Reports] Mouse liver perfusion was used to identify the effects of interstitial flow on hepatocyte proliferation ex vivo. Isolated hepatocytes in vitro were further exposed to varied shear stresses directly.
Hepatic Cell NewsNewsletters
Read more

Cholangiocarcinoma-on-a-Chip: A Human 3D Platform for Personalized Medicine

[JHEP Reports] Cholangiocarcinoma (CCA) tumor microenvironment was recapitulated on a microfluidic three-channel chip using primary CCA cells, cancer-associated fibroblasts, endothelial cells, and T cells isolated from CCA specimens.
Hepatic Cell NewsNewsletters
Read more
Brought to you by